Zepbound

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Q2 revenue topped $15 billion, prompting a higher full-year forecast following disappointing weight-loss results for its experimental oral obesity therapy.